Hope Rugo, MD, Helen Diller Family Comprehensive Cancer Center, talks on hot topics in breast cancer. In triple-negative breast cancer (TNBC), research is focusing on improving outcome in both metastatic and early stage setting. Several trials are being designed using antibody-drug conjugates (ADCs) in patients who don’t have a pathologic complete response (pCR) to neoadjuvant therapy, as well as individualizing and optimizing therapy based on patients tumor response, both by investigating shorter and less intensive regimens in the neoadjuvant setting and avoiding treatment in the post-neoadjuvant setting for patients who achieve pCR. Increasing data is uncovering which patients with HR-positive breast cancer benefit from immunotherapy and chemotherapy in the neoadjuvant setting. ADCs are being moved into the first-line setting, including trastuzumab deruxtecan which is also under investigation in the post-neoadjuvant and neoadjuvant setting. Additionally, focus on safety and patient-reported outcomes (PROs) is increasing. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
